Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT06615102 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Reducing Cardiac-surgery Associated Acute Kidney Injury Occurence by Administering Angiotensin II

Study acronym: PAN-AKI
StatusRecruiting
PhasePhase 3
Started
View on ClinicalTrials.gov ↗

Record History

  1. Trial status: Not Yet Recruiting to Recruiting
    • Study sites: 0 to 4
    • Start date changed from estimate of Jan 2025 to Mar 31, 2025
    • Secondary endpoints: details revised at 1 of 3 entries
    v2
  2. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
The study intervention focuses on exploring the use of angiotensin II as a primary vasopressor compared to norepinephrine in cardiac surgery patients to investigate whether angiotensin II can reduce the occurrence of moderate/severe acute kidney injury (AKI). Despite its potential, as suggested by trials involving surgical patients, there is currently no human data confirming its effectiveness in preventing moderate/severe AKI in this context. The intervention aims to address this gap by evaluating angiotensin II's impact compared to norepinephrine.
Trial Details
NCT Number NCT06615102
Lead Sponsor Universität Münster
Collaborators: German Research Foundation
Conditions
(from sponsor)		 Cardiac Surgery, Vasoplegia
Related terms Acute Kidney Injury, Vasoplegia
Enrollment 1,022 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov